International Journal of Preventive Medicine

LETTER TO EDITOR
Year
: 2020  |  Volume : 11  |  Issue : 1  |  Page : 186-

CYP1A1 M2 (A2455G) polymorphism with susceptibility to breast cancer


Beuy Joob1, Viroj Wiwanitkit2,  
1 Medical Center, Sanitation 1 Medical Academic Center, Bangkok, Thailand
2 Department of Biological Science, Joseph Ayobabalola University, Ikeji-Arakeji, Nigeria

Correspondence Address:
Beuy Joob
Sanitation 1 Medical Academic Center, Bangkok
Thailand




How to cite this article:
Joob B, Wiwanitkit V. CYP1A1 M2 (A2455G) polymorphism with susceptibility to breast cancer.Int J Prev Med 2020;11:186-186


How to cite this URL:
Joob B, Wiwanitkit V. CYP1A1 M2 (A2455G) polymorphism with susceptibility to breast cancer. Int J Prev Med [serial online] 2020 [cited 2022 Dec 4 ];11:186-186
Available from: https://www.ijpvmjournal.net/text.asp?2020/11/1/186/303213


Full Text



Dear Editor,

We read the publication on “Association of CYP1A1 M2 (A2455G) Polymorphism with Susceptibility to Breast Cancer in Mazandaran Province, Northern Iran: A Case–control Study” with a great interest.[1] Khalili-Tanha et al. concluded that “M2 allelic genotypes were significantly associated neither with breast cancer risk nor with clinicopathological characteristics in Mazandaran province.[1]” Indeed, the result from this study is concordant with a recent report from China.[2]

Basically, the genetic variant A2455G can result in change at molecular level. The change in molecular weight occurs and can further result in phenotypic expression. However, the important concern is whether there is an actual interrelationship between CYP1A1 and carcinogenesis process. Although the possible interrelation between CYP1A1 and carcinogenesis has been proposed for a long time,[3] there has never proven clarified pathophysiological process. In case that there is no direct pathophysiological linking between CYP1A1 biological process and carcinogenesis, the molecular alteration and genetic change cannot affect any carcinogenesis process.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1Khalili-Tanha G, Barzegar A, Nikbakhsh N, Ansari-Pirsaraei Z. Association of CYP1A1 M2 (A2455G) polymorphism with susceptibility to breast cancer in Mazandaran province, Northern Iran: A case–control study. Int J Prev Med 2019;10:92.
2Wu H, Ouyang Q, Tian C, Xie N, Cao M, Shui ZR. Cytochrome P450 1A1 (CYP1A1) gene polymorphisms and susceptibility to breast cancer: A meta-analysis in the Chinese population. Clin Lab 2017;63:67-72.
3Kawajiri K, Fujii-Kuriyama Y. P450 and human cancer. Jpn J Cancer Res 1991;82:1325-35.